Detection of Circulating HPV16 DNA as a Biomarker for Cervical Cancer by a Bead-Based HPV Genotyping Assay

Galati, Luisa; Combes, Jean‐Damien; Calvez‐Kelm, Florence Le; McKay‐Chopin, Sandrine; Forey, Nathalie; Ratel, Mathis; McKay, James; Waterboer, Tim; Schroeder, Lea; Clifford, Gary M.; Tommasino, Massimo; Gheit, Tarik

doi:10.1128/spectrum.01480-21

Cited by 16 publications

(13 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Applicationsmentioning

confidence: 99%

“…35 Galati et al assessed whether the magnetic bead-based HPV genotyping test for HPV16 can be utilized as a biomarker for cervical cancer (CC) in ddPCR. 119 Additionally, the detection of cell-free DNA (cfDNA) in saliva by ddPCR, which has strong sensitivity for HPV16-OPC, can help identify HPV-induced oropharyngeal cancer (OPC). 120,121 In addition to CTCs for liquid biopsy to diagnose cancer, ddPCR also detects mutated genes or tumor markers to allow a comprehensive determination of the extent of disease progression.…”

Section: Disease Diagnosismentioning

confidence: 99%

See 1 more Smart Citation

Advances in droplet digital polymerase chain reaction on microfluidic chips

Zhang

et al. 2023

Lab Chip

View full text Add to dashboard Cite

show abstract

Section: Applicationsmentioning

confidence: 99%

Section: Disease Diagnosismentioning

confidence: 99%

Advances in droplet digital polymerase chain reaction on microfluidic chips

Zhang

et al. 2023

Lab Chip

View full text Add to dashboard Cite

show abstract

“…In addition to detecting the intralesional HPV transcripts, the HPV circulating tumour DNA (HPV ctDNA) was proposed as a biomarker for the detection and disease monitoring of HPV-related cancers. One study suggests that the HPV16 ctDNA biomarker appeared to be highly specific; however, it lacks the sensitivity for the detection of cervical cancer, even for those at an advanced tumour stage [ 52 ].…”

Section: Detection Of Premalignancy and Malignancy Of The Uterine Cervixmentioning

confidence: 99%

Review of the Standard and Advanced Screening, Staging Systems and Treatment Modalities for Cervical Cancer

Boon

Luk

Xiao

et al. 2022

Cancers

View full text Add to dashboard Cite

Cancer arising from the uterine cervix is the fourth most common cause of cancer death among women worldwide. Almost 90% of cervical cancer mortality has occurred in low- and middle-income countries. One of the major aetiologies contributing to cervical cancer is the persistent infection by the cancer-causing types of the human papillomavirus. The disease is preventable if the premalignant lesion is detected early and managed effectively. In this review, we outlined the standard guidelines that have been introduced and implemented worldwide for decades, including the cytology, the HPV detection and genotyping, and the immunostaining of surrogate markers. In addition, the staging system used to classify the premalignancy and malignancy of the uterine cervix, as well as the safety and efficacy of the various treatment modalities in clinical trials for cervical cancers, are also discussed. In this millennial world, the advancements in computer-aided technology, including robotic modules and artificial intelligence (AI), are also incorporated into the screening, diagnostic, and treatment platforms. These innovations reduce the dependence on specialists and technologists, as well as the work burden and time incurred for sample processing. However, concerns over the practicality of these advancements remain, due to the high cost, lack of flexibility, and the judgment of a trained professional that is currently not replaceable by a machine.

show abstract

“…Campo et al concluded cell‐free human papillomavirus‐DNA (cfHPV‐DNA) represents a potential confirmatory and complementary assay for the positive results of positron emission tomography/computed tomography (PET/CT) scan 20 . In addition, Balachandra et al and Galati et al indicated that HPV16 E6 antibodies and circulating HPV‐16 DNA are valuable candidate blood‐based biomarkers of HPV‐associated cancers 19,23 . Both next‐generation sequencing (NGS) and digital droplet polymerase chain reaction (ddPCR) as high throughput techniques are major methods to study HPV ctDNA and have been demonstrated to be more accurate than quantitative PCR (qPCR) 13 .…”

Section: Introductionmentioning

confidence: 99%

“…Both next‐generation sequencing (NGS) and digital droplet polymerase chain reaction (ddPCR) as high throughput techniques are major methods to study HPV ctDNA and have been demonstrated to be more accurate than quantitative PCR (qPCR) 13 . The use of ddPCR, or a bead‐based assay such like the E7‐MPG, in liquid biopsy improves the diagnostic value of HPV ctDNA significantly 21,23,24 . There is a discrepancy in the data published on HPV ctDNA by OMIC techniques as a predictive biomarker in the surveillance of HPV‐related cancers 25,26 .…”

Section: Introductionmentioning

confidence: 99%

Predictive impact of human papillomavirus circulating tumorDNAin treatment response monitoring ofHPV‐associated cancers; a meta‐analysis on recurrent event endpoints

et al. 2023

Self Cite

View full text Add to dashboard Cite

BackgroundHPV infection can cause cancer, and standard treatments often result in recurrence. The extent to which liquid biopsy using HPV circulating tumor DNA (HPV ctDNA) can be used as a promising marker for predicting recurrence in HPV‐related cancers remains to be validated. Here we conducted a systematic review and meta‐analysis to assess its effectiveness in predicting treatment response.MethodsWe conducted a systematic literature search of online databases, including PubMed, Embase, Scopus, and the Cochrane Library, up to December 2022. The goal was to identify survival studies that evaluated the potential of plasma HPV ctDNA at baseline and end‐of‐treatment (EoT) in predicting recurrence of related cancers. Hazard ratios were estimated directly from models or extracted from Kaplan–Meier plots.ResultsThe pooled effect of HPV ctDNA presence on disease recurrence was estimated to be HR = 7.97 (95% CI: [3.74, 17.01]). Subgroup analysis showed that the risk of recurrence was HR = 2.17 (95% CI: [1.07, 4.41]) for baseline‐positive cases and HR = 13.21 (95% CI: [6.62, 26.36]) for EoT‐positive cases. Significant associations were also observed between recurrence of oropharyngeal squamous cell carcinoma (HR = 12.25 (95% CI: [2.62, 57.36])) and cervical cancer (HR = 4.60 (95% CI: [2.08, 10.17])) in plasma HPV ctDNA‐positive patients.ConclusionsThe study found that HPV ctDNA detection can predict the rate of relapse or recurrence after treatment, with post‐treatment measurement being more effective than baseline assessment. HPV ctDNA could be used as a surrogate or incorporated with other methods for detecting residual disease.

show abstract

Detection of Circulating HPV16 DNA as a Biomarker for Cervical Cancer by a Bead-Based HPV Genotyping Assay

Cited by 16 publications

References 53 publications

Advances in droplet digital polymerase chain reaction on microfluidic chips

Advances in droplet digital polymerase chain reaction on microfluidic chips

Review of the Standard and Advanced Screening, Staging Systems and Treatment Modalities for Cervical Cancer

Predictive impact of human papillomavirus circulating tumorDNAin treatment response monitoring ofHPV‐associated cancers; a meta‐analysis on recurrent event endpoints

Contact Info

Product

Resources

About